Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...

Pfizer (NYSE:PFE) recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 clinical study of the innovative MesoC2 drug at the ASCO Annual Meeting, and ...

Pfizer Inc (NYSE:PFE) shares are moving higher Tuesday following multiple developments. Here's a look at what's going on.

For Pfizer, the consensus sales estimate for the current quarter of $17.5 billion indicates a year-over-year change of +22.8%. For the current and next fiscal years, $63.36 billion and $62.98 ...

The stock's fall snapped a four-day winning streak.

But I actually see this as a risk factor since according to my earlier analysis, Pfizer ... company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is ...

Diving into Analyst Ratings: An In-Depth Exploration The analysis of recent analyst ... Revenue Growth: Over the 3M period, Pfizer showcased positive performance, achieving a revenue growth ...

Pfizer’s PFE $13.7 billion in revenue (an ... Management said that full-year performance is trending toward the high end of EPS guidance. Cardiomyopathy drugs including Vyndaqel grew 31% ...

Last year was a strong one in terms of performance and execution by Pfizer, even though its stock took a hit in 2023 due to a decline in revenues and profits. It saw improved performance of its ...

Below is some historical data on the post-earnings performance of Pfizer stock compared to the stock performance of peers that reported their earnings just before Pfizer. For a fair comparison ...